Company / R&D per Share
GERON CORP R&D per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.16
FY2024
5-year range
$0.07 / $0.32
FY2020-FY2024
Trend
-49.9%
vs FY2023
Sector context
#194 of 208
Health Care
What the data says
Among 208 Health Care companies, GERON CORP is in the bottom 7% for r&d per share. R&D per Share has fluctuated over the past 10 years, ranging from $0.06 in FY2019 to $0.32 in FY2023.
Based on SEC 10-K filings.
0.16 in FY2024 with a 5-year CAGR of +22.1%.
Declined from $0.30 to $0.16 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -1.4%
- 5-Year CAGR
- +22.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 208This company $0.16 Sector average $12.19
▼
-98.7% below sector average
Key checks
Key Insights
- In FY2024, r&d per share decreased 49.9% year-over-year.
- Ranks #194 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2023.
- Lowest r&d per share in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.16 | -49.9% |
| FY2023 | $0.32 | +8.6% |
| FY2022 | $0.30 | +76.0% |
| FY2021 | $0.17 | +149.4% |
| FY2020 | $0.07 | +13.6% |
| FY2019 | $0.06 | -47.6% |
| FY2018 | $0.11 | +0.8% |
| FY2017 | $0.11 | -14.1% |
| FY2016 | $0.13 | -11.3% |
| FY2015 | $0.15 | -62.6% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026